Walgreens to acquire CuraScript Infusion
Walgreens, the USA's largest drugstore chain, acting through its subsidiary OptionCare Enterprises, is to acquire CuraScript Infusion Pharmacy, for an undisclosed fee.
CuraScript is currently the pharmacy benefit management company Express Scripts' wholly-owned, home infusion services division. It is expected to pass into the hands of OptionCare early next month.
The acquired division is one of the USA's largest providers of infusion services. It has operated for over 15 years and supports patients who require complex therapies including anti-viral, immune deficiency, inotropic, chemotherapy and pain management treatments. Walgreens will acquire each of CuraScript's 12 facilities located in the states of Alabama, Indiana, Kentucky, Missouri, Ohio and Tennessee. They will be added to the existing 6,252 Walgreens stores that already operate in 49 US states, Columbia and Puerto Rico.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze